TARRYTOWN, N.Y., Jan. 19, 2021 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) today
announced that it will report its fourth quarter and full year 2020
financial and operating results on Friday,
February 5, 2021, before the U.S. financial markets
open. The Company will host a conference call and
simultaneous webcast at 8:30 AM Eastern
Time that day.
Conference Call Information
To access this call, dial
(888) 660-6127 (U.S.) or (973) 890-8355 (International), conference
ID 1580376. A link to the webcast may be accessed from the
'Investors and Media' page of Regeneron's website at
http://investor.regeneron.com/events.cfm. A replay of the
conference call and webcast will be archived on the Company's
website for at least 30 days.
About Regeneron
Regeneron (NASDAQ:
REGN) is a leading biotechnology company that invents
life-transforming medicines for people with serious diseases.
Founded and led for over 30 years by physician-scientists, our
unique ability to repeatedly and consistently translate science
into medicine has led to eight FDA-approved treatments and numerous
product candidates in development, all of which were homegrown in
our laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, infectious
diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our
proprietary VelociSuite® technologies,
such as VelocImmune®, which uses unique
genetically-humanized mice to produce optimized fully-human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about the company, please
visit www.regeneron.com or follow @Regeneron on
Twitter.
Contact Information:
Investor Relations
Justin Holko
914.847.7786
justin.holko@regeneron.com
Corporate Communications
Hala Mirza
914.847.3422
hala.mirza@regeneron.com
View original
content:http://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2020-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-5-2021-301211100.html
SOURCE Regeneron Pharmaceuticals, Inc.